[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Outperforms Broader Market: What You Need to Know",
    "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=b9ea8c9ab9fe6408d56f17e925fb6e91231b36c09c73b0d9391fdcc1dacc9a9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750974604,
      "headline": "Moderna (MRNA) Outperforms Broader Market: What You Need to Know",
      "id": 135577431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=b9ea8c9ab9fe6408d56f17e925fb6e91231b36c09c73b0d9391fdcc1dacc9a9d"
    }
  },
  {
    "ts": null,
    "headline": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
    "summary": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
    "url": "https://finnhub.io/api/news?id=d9355b04643df5347e9fc158fec2387c4041b7cf91cb73ecf64d3625aeefa72c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750948080,
      "headline": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
      "id": 135593337,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
      "url": "https://finnhub.io/api/news?id=d9355b04643df5347e9fc158fec2387c4041b7cf91cb73ecf64d3625aeefa72c"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Moderna’s Q1 Earnings Call",
    "summary": "Moderna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations and declined sharply versus the prior year. Management attributed the performance primarily to the seasonal nature of respiratory vaccine sales and lower overall COVID vaccination rates, which have become more routine rather than urgent. CEO Stephane Bancel pointed to progress in cost reduction efforts, highlighting a 19% reduction in combined cost of sales, research and de",
    "url": "https://finnhub.io/api/news?id=c91a0312d75888c6a6acef5fdf6848fb2c8bf98de738c9ddb5ddd362a30b28d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750920916,
      "headline": "The Top 5 Analyst Questions From Moderna’s Q1 Earnings Call",
      "id": 135554786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations and declined sharply versus the prior year. Management attributed the performance primarily to the seasonal nature of respiratory vaccine sales and lower overall COVID vaccination rates, which have become more routine rather than urgent. CEO Stephane Bancel pointed to progress in cost reduction efforts, highlighting a 19% reduction in combined cost of sales, research and de",
      "url": "https://finnhub.io/api/news?id=c91a0312d75888c6a6acef5fdf6848fb2c8bf98de738c9ddb5ddd362a30b28d9"
    }
  }
]